Eric Bjerkholt
CIK: 0001197350
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (38 total)
- Sep 14, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct9.9K shares at avg. $98.37$978K - Sep 11, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct18.3K shares- - Aug 11, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct6K shares at avg. $99.90$600K - Jul 6, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct3.1K shares at avg. $121.67$380K - Jul 6, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct1K shares at avg. $122.43$128K - Jul 6, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct528 shares at avg. $123.84$65K - Jul 6, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct300 shares at avg. $124.94$37K - Jun 9, 2026CERS
CERUS CORP
Sale(S)Direct20.5K shares at avg. $2.60$53K - Jun 9, 2026MGX
Metagenomi Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
21K shares- - Jun 9, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct2.4K shares at avg. $26.49$63K - Jun 8, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct1.2K shares at avg. $93.95$110K - Jun 8, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct1.6K shares at avg. $95.12$149K - Jun 8, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct2.3K shares at avg. $92.84$210K - Jun 2, 2026CERS
CERUS CORP
Award(A)Direct60K shares- - May 13, 2026SRZN
Surrozen, Inc./DE
Award(A)DirectDirector Stock Option (right to buy)
5.6K shares- - Mar 16, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct7.3K shares at avg. $91.98$670K - Mar 15, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct13.3K shares- - Jan 28, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectPerformance Restricted Stock Units
20K shares- - Jan 28, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
11.8K shares- - Jan 28, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
18.1K shares- - Jan 26, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct1.1K shares at avg. $96.19$101K - Jan 23, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct2.7K shares- - Jan 22, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct1.4K shares at avg. $93.33$133K - Jan 21, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct3.3K shares- - Sep 12, 2025MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct9.6K shares at avg. $76.01$728K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 14, 2026 |  MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 9,943 | $98.37 | $978,093 | Direct |
| Sep 11, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 18,333 | - | $0 | Direct |
| Aug 11, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 6,001 | $99.90 | $599,510 | Direct |
| Jul 6, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 3,124 | $121.67 | $380,097 | Direct |
| Jul 6, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 1,048 | $122.43 | $128,307 | Direct |
| Jul 6, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 528 | $123.84 | $65,388 | Direct |
| Jul 6, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 300 | $124.94 | $37,482 | Direct |
| Jun 9, 2026 |  CERS CERUS CORP | Sale(S) | 20,454 | $2.60 | $53,180 | Direct |
| Jun 9, 2026 |  MGX Metagenomi Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 21,000 | - | - | Direct |
| Jun 9, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 2,393 | $26.49 | $63,391 | Direct |
| Jun 8, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 1,175 | $93.95 | $110,391 | Direct |
| Jun 8, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 1,567 | $95.12 | $149,053 | Direct |
| Jun 8, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 2,258 | $92.84 | $209,633 | Direct |
| Jun 2, 2026 | CERS CERUS CORP | Award(A) | 60,000 | - | $0 | Direct |
| May 13, 2026 |  SRZN Surrozen, Inc./DE | Award(A) Director Stock Option (right to buy) | 5,550 | - | - | Direct |
| Mar 16, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 7,287 | $91.98 | $670,243 | Direct |
| Mar 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 13,334 | - | $0 | Direct |
| Jan 28, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Performance Restricted Stock Units | 20,000 | - | - | Direct |
| Jan 28, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 11,760 | - | - | Direct |
| Jan 28, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 18,140 | - | - | Direct |
| Jan 26, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 1,053 | $96.19 | $101,290 | Direct |
| Jan 23, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 2,667 | - | $0 | Direct |
| Jan 22, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 1,421 | $93.33 | $132,615 | Direct |
| Jan 21, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 3,334 | - | $0 | Direct |
| Sep 12, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 9,578 | $76.01 | $728,024 | Direct |
1-25 of 38 transactions
About BJERKHOLT ERIC
BJERKHOLT ERIC (SEC CIK 0001197350) files insider reports with the SEC as CHIEF FINANCIAL OFFICER of Mirum Pharmaceuticals, Inc. (MIRM), Director of CERUS CORP (CERS) and Director of Metagenomi Therapeutics, Inc. (MGX). Signal8 also holds filings tied to 1 other company.
Signal8 holds 24 ownership filings by BJERKHOLT ERIC (1 Form 3, 23 Form 4), filed between Sep 12, 2024 and Sep 15, 2026. Those filings report 38 transactions, from Sep 11, 2024 to Sep 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on BJERKHOLT ERIC's filings is in FOSTER CITY, CA.
Recent filings by BJERKHOLT ERIC
- Sep 14, 2026: Open-market sale of MIRM shares (Form 4, code S).
- Sep 11, 2026: Option exercise of MIRM shares (Form 4, code M).
- Aug 11, 2026: Open-market sale of MIRM shares (Form 4, code S).
- Jul 6, 2026: Open-market sales of MIRM shares (4 lines, Form 4, code S).
- Jun 9, 2026: Open-market sale of CERS shares (Form 4, code S).
Other insiders filing for Mirum Pharmaceuticals, Inc. (MIRM)
- Howe Jolanda, SVP, GLOBAL CONTROLLER
- Myers Robert Paul, Chief Medical Officer
- Peetz Christopher, CHIEF EXECUTIVE OFFICER
- Walbert Timothy P, Director
- Cardon Lon, Director
- Ramasastry Saira, Director